Diabetes Insights - Breakthroughs and Innovators

In this episode, Prof. João Filipe Raposo (Portugal) and Prof. Harald Sourij (Austria) join Vivienne Parry to debate one of the most discussed topics in modern diabetes care: the role of artificial intelligence.

The conversation explores how AI is already being used to support diabetes management, including automated insulin delivery systems, continuous glucose monitoring and risk prediction. At the same time, the speakers examine the challenges of translating AI research into everyday clinical practice, highlighting the need for robust evidence, high-quality data and meaningful patient outcomes.

They also discuss data privacy, regulation, patient trust and why human expertise and empathy remain central to diabetes care. Discover how AI could shape the future of diabetes management and why careful implementation matters just as much as technological innovation.

In this episode, EASD tv host Vivienne Parry speaks with Prof. Daisuke Yabe (Kyoto University) about the growing global impact of EASD and the importance of international collaboration in diabetes research.

Prof. Yabe explains the key differences between diabetes phenotypes in Europe and East Asia, highlighting how obesity, insulin resistance and beta cell dysfunction vary across populations. He discusses how sharing these perspectives is driving better research, stronger international partnerships and improved diabetes care worldwide.

The conversation also explores one of the most exciting developments in regenerative medicine: iPS cell-derived islet transplantation. Professor Yabe shares how clinical trials in Japan are addressing donor shortages using induced pluripotent stem cells and discusses the progress being made towards more scalable cell therapies for people living with type 1 diabetes.

In this episode, Prof. Thomas Karagiannis and Dr Francesco Zaccardi take us behind the scenes of clinical guideline development at EASD. As methodologists involved in creating the first EASD clinical guidelines, they explain how rigorous evidence review, transparent processes and careful management of conflicts of interest help ensure recommendations are trustworthy and evidence-based.

The discussion explores the newly developed guideline on diabetes distress, upcoming guidance on continuous glucose monitoring in type 2 diabetes, and future recommendations on diabetes prevention. Along the way, Thomas and Francesco highlight the importance of patient involvement, the role of systematic reviews and meta-analyses, and the emerging opportunities for artificial intelligence in guideline development.

Join us for an insightful look at the work that transforms scientific evidence into practical recommendations that can shape diabetes care across Europe and beyond.

In this episode, Dame Melanie Davies and Prof. Amanda Adler discuss the development of a new EASD clinical guideline on continuous glucose monitoring (CGM) in people living with type 2 diabetes.

As CGM becomes increasingly available, clinicians, researchers, and policymakers are seeking clear evidence-based guidance on its role in diabetes management. The discussion explores why CGM was selected as a priority topic, how guideline questions are developed, the importance of patient involvement, and the rigorous process used to evaluate clinical evidence.

The conversation also highlights the broader outcomes that matter to people living with diabetes (including quality of life, confidence and behaviour change) and examines how future recommendations could influence healthcare policy and access to diabetes technology across Europe and beyond.

In this episode, Prof. Eberhard Standl marks an extraordinary milestone - 50 years since attending his first EASD Congress. Looking back on a career spanning five decades, he shares how diabetes care has evolved from the challenges of diabetic ketoacidosis in the 1970s to today's advances in continuous glucose monitoring, hybrid closed-loop systems, immunotherapies, and the potential reversal of type 2 diabetes.

Prof. Standl discusses the enduring importance of lifestyle interventions, the value of long-term partnerships between clinicians and people living with diabetes, and emerging research linking diabetes, obesity, metabolism, and cancer. He also reflects on the collaborative spirit of the diabetes research community and the exciting possibilities that lie ahead for both type 1 and type 2 diabetes.